

ForPatients

by Roche

Huntington Disease (HD)

An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of RO7234292 (RG6042) in Patients With Huntington's Disease

Trial Status
Completed

Trial Runs In
8 Countries

Trial Identifier
NCT03842969 2018-003898-94
BN40955

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or Genentech-sponsored studies in the Huntington's disease (HD) in the development program for RG6042.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03842969 2018-003898-94 BN40955
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥25 Years

Healthy Volunteers
No
